WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 530648

CAS#: 1627902-21-9

Description: JNJ-54175446 is a potent and selective P2X7 Receptor Antagonist. JNJ-54175446 is potent, stable in liver microsomes and has an acceptable protein binding profile. JNJ-54175446 is highly permeable and has no evidence of efflux as measured by a Caco-2 cell line. JNJ-54175446 efficiently binds to recombinant rat and human P2X7 and to native tissues in both human and rat. JNJ-54175446 also inhibited P2X7 activity in human, rat, dog, mouse, and macaque Ca2+ flux assays and inhibited IL1-β release in human peripheral blood monocytes (pIC50 of 7.7 ± 0.1) and in human whole blood (pIC50 of 8.1 ± 0.1).

Chemical Structure

CAS# 1627902-21-9

Theoretical Analysis

MedKoo Cat#: 530648
Name: JNJ-54175446
CAS#: 1627902-21-9
Chemical Formula: C18H13ClF4N6O
Exact Mass: 440.0775
Molecular Weight: 440.7866
Elemental Analysis: C, 49.05; H, 2.97; Cl, 8.04; F, 17.24; N, 19.07; O, 3.63

Price and Availability

Size Price Availability Quantity
1.0mg USD 750.0 2 Weeks
5.0mg USD 1550.0 2 Weeks
Bulk inquiry

Synonym: JNJ-54175446; JNJ 54175446; JNJ54175446

IUPAC/Chemical Name: (R)-(2-chloro-3-(trifluoromethyl)phenyl)(1-(5-fluoropyrimidin-2-yl)-4-methyl-1,4,6,7-tetrahydro-5H-[1,2,3]triazolo[4,5-c]pyridin-5-yl)methanone


InChi Code: InChI=1S/C18H13ClF4N6O/c1-9-15-13(29(27-26-15)17-24-7-10(20)8-25-17)5-6-28(9)16(30)11-3-2-4-12(14(11)19)18(21,22)23/h2-4,7-9H,5-6H2,1H3/t9-/m1/s1

SMILES Code: ClC1=C(C(F)(F)F)C=CC=C1C(N(CC2)[C@H](C)C(N=N3)=C2N3C4=NC=C(C=N4)F)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 440.7866 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Letavic MA, Savall BM, Allison BD, Aliusio L, Andrés JI, De Angelis M, Ao H,
Beauchamp DA, Bonaventure P, Bryant S, Carruthers NI, Ceusters M, Coe KJ, Dvorak
CA, Fraser I, Gelin CF, Koudriakova T, Liang J, Lord B, Lovenberg TW, Otieno M,
Schoetens F, Swanson DM, Wang Q, Wickenden AD, Bhattacharya A.
4-Methyl-6,7-dihydro-4H-triazolo[4,5-c]pyridine-based P2X7 Receptor Antagonists:
Optimization of Pharmacokinetic Properties Leading to the Identification of a
Clinical Candidate. J Med Chem. 2017 May 11. doi: 10.1021/acs.jmedchem.7b00408.
[Epub ahead of print] PubMed PMID: 28493698.

Additional Information

Inhibition of P2X7 and P2X7 mediated IL-1β release might therefore represent a novel approach to the treatment of mood disorders.
JNJ-54175446 had excellent PK in multiple species, a very low predicted human efficacious dose, and an excellent preclinical safety profile, the compound was nominated for clinical development and has since been dosed in healthy volunteers at single doses from 0.5 mg to 600 mg.